ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,146.86
-0.21%
Dow Jones
38,589.16
-0.15%
Gold vs US Dollar
2,333.015
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,266.43
0.40%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. MIRA Pharmaceuticals Inc (MIRA)

  7. MIRA Pharmaceuticals Inc (MIRA) News

MIRA Pharmaceuticals (MIRA)

MIRA Pharmaceuticals Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:MIRA
DateTimeSourceHeadlineSymbolCompany
10/06/202413:30PR Newswire (US)Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This YearNASDAQ:MIRAMIRA Pharmaceuticals Inc
30/05/202423:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
29/05/202413:45PR Newswire (US)Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled SubstanceNASDAQ:MIRAMIRA Pharmaceuticals Inc
29/05/202413:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
22/05/202422:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
21/05/202413:45PR Newswire (US)MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine AnalogNASDAQ:MIRAMIRA Pharmaceuticals Inc
20/05/202413:00PR Newswire (US)Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine AnalogNASDAQ:MIRAMIRA Pharmaceuticals Inc
13/05/202421:31Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MIRAMIRA Pharmaceuticals Inc
02/04/202413:00PR Newswire (US)Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND SubmissionNASDAQ:MIRAMIRA Pharmaceuticals Inc
21/03/202415:04PR Newswire (US)MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific AdvisorNASDAQ:MIRAMIRA Pharmaceuticals Inc
07/03/202421:45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/02/202413:30PR Newswire (US)MIRA Pharmaceuticals Provides Corporate UpdateNASDAQ:MIRAMIRA Pharmaceuticals Inc
17/01/202421:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
28/12/202305:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:MIRAMIRA Pharmaceuticals Inc
27/12/202322:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
27/12/202322:27Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MIRAMIRA Pharmaceuticals Inc
18/12/202321:50Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:MIRAMIRA Pharmaceuticals Inc
04/12/202313:00PR Newswire (US)MIRA Pharmaceuticals Releases Breakthrough Data from Artificial Intelligence SimulationsNASDAQ:MIRAMIRA Pharmaceuticals Inc
01/12/202322:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
29/11/202313:00PR Newswire (US)MIRA Pharmaceuticals Announces Ketamir-2's Oral Bioavailability Predicted to be 80%NASDAQ:MIRAMIRA Pharmaceuticals Inc
21/11/202315:42PR Newswire (US)MIRA Pharmaceuticals To Host Shareholder Update Call on Tuesday, December 5, 2023 at 11:30 a.m. Eastern TimeNASDAQ:MIRAMIRA Pharmaceuticals Inc
21/11/202315:09PR Newswire (US)MIRA Pharmaceuticals Announces Paradigm-Shift in Cognitive Enhancement with MIRA1aNASDAQ:MIRAMIRA Pharmaceuticals Inc
20/11/202321:18Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:MIRAMIRA Pharmaceuticals Inc
20/11/202321:15Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:MIRAMIRA Pharmaceuticals Inc
20/11/202313:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MIRAMIRA Pharmaceuticals Inc
20/11/202313:00PR Newswire (US)MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2NASDAQ:MIRAMIRA Pharmaceuticals Inc
18/09/202313:30PR Newswire (US)MIRA Pharmaceuticals Shows its Prescription Pill More Palatable and Potent Than PotNASDAQ:MIRAMIRA Pharmaceuticals Inc
05/09/202313:31PR Newswire (US)MIRA Pharmaceuticals and MZ Group Partner to Strengthen Investor Relations and Shareholder Communication EffortsNASDAQ:MIRAMIRA Pharmaceuticals Inc
31/08/202313:31PR Newswire (US)MIRA Pharmaceuticals to Participate in 6th Annual Cannabinoid-Derived Drug Development SummitNASDAQ:MIRAMIRA Pharmaceuticals Inc
29/08/202316:39PR Newswire (US)MIRA Pharmaceuticals to Host Virtual Roadshow Webinar on Monday, September 11, 2023 at 1:00 p.m. Eastern TimeNASDAQ:MIRAMIRA Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:MIRA

Your Recent History

LSE
PANR
Pantheon Resources
LSE
AAZ
Anglo Asian Mining
LSE
VOD
Vodafone
LSE
INSG
Insig Ai
LSE
SBTX
Skinbiotherapeutics
LSE
ENET
Ethernity Networks
LSE
GOLD
LSE
HUM
Hummingbird Resources
LSE
GPM
Golden Prospect Precious...
LSE
SDRY
Superdry
LSE
PHNX
Phoenix
LSE
SRSP
Sirius Petroleum
LSE
BP.
Bp
LSE
CNR
Condor Gold
LSE
LLOY
Lloyds Banking
LSE
BT.A
Bt
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved